Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05602597 · ClinicalTrials.gov registry record · Phase 1
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
A Phase 1 study, sponsored by Hutchmed.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT05602597 is a Phase 1 study that has completed, run by Hutchmed. The registered enrollment target is 59 participants.
The verdict
NCT05602597, a Phase 1 study, has completed, sponsored by Hutchmed.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
An open-label study to determine effect of Itraconazole, Fluconazole, Rifampin, and Rabeprazole on the PK of HMPL-689
Interventions
- DRUG Itraconazole 200 mg
- DRUG Fluconazole 400 mg
- DRUG Rifampin 600 mg
- DRUG Rabeprazole 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2022-08-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05602597
The ClinicalTrials.gov registry entry for NCT05602597 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hutchmed, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Itraconazole 200 mg is the first listed.
NCT05602597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05602597 about?
NCT05602597 is a clinical study titled "HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI". An open-label study to determine effect of Itraconazole, Fluconazole, Rifampin, and Rabeprazole on the PK of HMPL-689
What is the current status of trial NCT05602597?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2022-06-01. Estimated completion is 2022-08-06.
What interventions are being tested in trial NCT05602597?
The interventions under investigation include: Itraconazole 200 mg (DRUG), Fluconazole 400 mg (DRUG), Rifampin 600 mg (DRUG), Rabeprazole 40 mg (DRUG).
Who is sponsoring clinical trial NCT05602597?
This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.